Facebook Facebook Facebook Facebook
09
Apr 15

Jackson is first boy with Duchenne to receive Follistatin

On Monday, April 6, 2015, our very own Jackson was the first of six boys in the world to receive an experimental therapy called Follistatin.  Developed by a team led by Dr. Jerry Mendell from Nationwide Children’s Hospital here in Columbus, Ohio, Follistatin in a non-mutation specific, gene therapy that blocks myostatin, a negative growth factor in muscle tissue.  In previous trials, most patients improved their ability to walk, gained muscle strength, and experienced a reduction in fibrosis and inflammation so often present with muscle disease.  The Duchenne arm of the Follistatin trial was funded by the Duchenne Alliance, of which Little Hercules Foundation is a member.  This promising therapy is a great example of how foundations can partner directly with the research community to move promising therapies through the pipeline FASTER! We will post updates as to Jackson’s progress.

Jack pre op pic

Sign up for Updates

No spam. Just periodic updates on what we are doing and how you can help.

Close
loading...